Back to Journals » Patient Related Outcome Measures » Volume 6

User preference for a portable syringe pump for iloprost infusion

Authors Laria A, Lurati AM, Re KA, Marrazza M, Mazzocchi D, Farina A, Scarpellini M

Received 24 January 2015

Accepted for publication 8 April 2015

Published 19 May 2015 Volume 2015:6 Pages 139—144

DOI https://doi.org/10.2147/PROM.S81473

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Robert Howland


Antonella Laria,1 Alfredo Maria Lurati,1 Katia Angela Re,1 Maria Grazia Marrazza,1 Daniela Mazzocchi,1 Alberto Farina,2 Magda Scarpellini,1

1Department of Rheumatology, Fornaroli Hospital, Magenta, Milan, Italy; 2Medical Affairs Department, Italfarmaco S.p.A., Cinisello Balsamo, Milan, Italy

Purpose: Administration of intravenous iloprost – a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy – requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient mobility is considerably restricted due to the size and fixity of traditional syringe pumps. The aim of this study was to evaluate the satisfaction level of patients and nurses, after the introduction of a new portable syringe pump (Infonde®, Italfarmaco S.p.A., Milan, Italy) at the Department of Rheumatology, Magenta Hospital, Milan, Italy.
Patients and methods: Thirty-four consecutive SSc patients receiving stable therapy with iloprost, previously administered with a fixed pump, were treated using the portable Infonde® pump. Patients (n=34) and nurses (n=4) were asked to answer a nine- and six-item questionnaire, respectively, to assess the satisfaction of the administration comparing the new device versus the previous one. The health care staff of the ward developed the questionnaire, and the response scores ranged from 0 (fixed device better) to 10 (portable device better); thus a score >5 indicates a preference for Infonde®.
Results: Patients' answers indicated a preference towards the new portable syringe pump, versus the previous fixed pump. Questionnaires administered to patients generated a total of 306 responses, with over 95% of the responses in the range 8–10, of which 89% had a score equal to 10. The responses of nurses showed a score equal to 10 in 100% cases. No significant adverse events were recorded, indicating no change in the tolerability profile of the drug.
Conclusion: Iloprost administration with Infonde® pump was preferred by both patients and health care professionals, and was well tolerated. The possibility to perform daily activities and the freedom of movement suggest a positive impact of Infonde® on the treatment, with a potential favorable effect on the quality of life of patients during the many hours spent receiving the infusion.

Keywords: scleroderma, quality of life, Raynaud's phenomenon, delivery device

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]